rss
Br J Ophthalmol 2009;93:1075-1080 doi:10.1136/bjo.2008.145128
  • Original Article
  • Laboratory science

Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation

  1. B O Bachmann1,2,
  2. E Luetjen-Drecoll1,
  3. F Bock2,
  4. S J Wiegand3,
  5. D Hos1,
  6. R Dana4,
  7. F E Kruse2,
  8. C Cursiefen2,4
  1. 1
    Department of Anatomy II, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
  2. 2
    Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
  3. 3
    Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA
  4. 4
    Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr C Cursiefen, Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg, Schwabachanlage 6, 91054 Erlangen, Germany; ccursiefen{at}yahoo.com
  • Accepted 22 January 2009
  • Published Online First 17 February 2009

Abstract

Background: High-risk keratoplasties are usually performed after an uninflamed and quiescent interval in corneas with partly regressed blood and lymphatic vessels. We analysed whether the inhibition of post-keratoplasty revascularisation in mice with partly regressed corneal vessels (“intermediate-risk”) improves graft survival.

Methods: Three interrupted stromal sutures (11-0) in corneas of Balb/c mice (6–8 weeks old) were placed for 6 weeks. Six months after suture removal, penetrating keratoplasty was performed with C57BL/6 donors. The treatment group received a vascular endothelial growth factor-A specific cytokine trap (VEGF Trap) intraperitoneally at days 0, 4, 7 and 14 after keratoplasty (25 mg/kg per mouse; controls received equal amounts of Fc protein). Pathological haemangiogenesis and lymphangiogenesis prior to as well as 3 days or 8 weeks after keratoplasty and graft survival were analysed.

Results: Three days after keratoplasty corneal revascularisation was sufficiently reduced by VEGF Trap (haem-vascularised areas 42.7% reduction; lymph-vascularised areas 54.7% reduction). Survival proportions 8 weeks after keratoplasty were 36% in the treatment group compared with 9% in the control group (n = 11; p<0.05). At that time no differences in haemangiogenesis or lymphangiogenesis were observed between the two groups.

Conclusion: Early transient postoperative induction of haemangiogenesis and lymphangiogenesis and reformation of regressed corneal blood and lymphatic vessels are important for transplant rejections after “intermediate-risk” corneal transplantation.

Footnotes

  • Funding German Research Council (Deutsche Forschungsgemeinschaft Grants Cu 47/1-1 and Cu 47/1-2), National Eye Institute (Grant EY10765), Interdisciplinary Center for Clinical Research (IZKF) Erlangen (Project A9 and “Rotation Grant” (B O Bachman)), ELAN fund for Science and Teaching Erlangen.

  • Competing interests VEGF Trap was provided by Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

  • Ethics approval All animals were treated in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.